

Fragilis Rabbit mAb [2ZNM]

Cat NO. :A51450

Information:

Applications	Reactivity:	UniProt ID:	MW(kDa)	Host	Isotype	Size
WB,IHC	H	Q01628	15 kDa	Rabbit	IgG	100ul,200ul

Applications detail:

Application	Dilution
WB	1:1000-2000
IHC	1:100,
The optimal dilutions should be determined by the end user	

Conjugate:

UnConjugate

Form:

Liquid

sensitivity:

Endogenous

Purification:

Protein A purification

Specificity:

Antibody is produced by immunizing animals with a synthetic peptide of Human Fragilis.

Storage buffer and conditions:

Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol (buffer) .

Shipped at 4°C. Store at -20°C or -80°C.

Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

Tissue specificity:

Subcellular location:

Cell membrane,Single-pass type II membrane protein. Late endosome membrane,Single-pass type II membrane protein. Early endosome membrane,Single-pass type II membrane protein. Lysosome

Function:

Introduction: **WB:** Western Blot **IP:** Immunoprecipitation **IHC:** Immunohistochemistry **ChIP:** Chromatin Immunoprecipitation **ICC/IF:** Immunocytochemistry/Immunofluorescence **F:** Flow Cytometry


Cross Reactivity: **H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Ml:** mink **C:** chicken **Dm** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Hr:** horse

For Research Use Only. Not For Use In Diagnostic Procedures.

IFN-induced antiviral protein which disrupts intracellular cholesterol homeostasis. Inhibits the entry of viruses to the host cell cytoplasm by preventing viral fusion with cholesterol depleted endosomes. May inactivate new enveloped viruses which buds out of the infected cell, by letting them go out with a cholesterol depleted membrane. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:26354436, PubMed:33270927, PubMed:33239446). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33270927). Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436). Exerts opposing activities on SARS-CoV-2, including amphipathicity-dependent restriction of virus at endosomes and amphipathicity-independent enhancement of infection at the plasma membrane (PubMed:33270927)..

Validation Data:

Fragilis Rabbit mAb [2ZNM] Images



Western blot (SDS PAGE) analysis of extracts from HeLa cells lysates using Fragilis Rabbit mAb [2ZNM] at dilution of 1:1000 incubated at 4°C overnight

View more information on <http://naturebios.com>

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 1% w/v Milk, 1X TBST at 4°C overnight.